A US sen­a­tor calls out a lit­tle biotech for price goug­ing. But will it change any­thing?

A lit­tle known biotech called Strong­bridge Bio­phar­ma has at­tract­ed the at­ten­tion of a promi­nent US sen­a­tor who would like to make the com­pa­ny the lat­est poster child for price goug­ing in the phar­ma world.

Ear­li­er this week the Wash­ing­ton Post pub­lished a re­port which de­tailed how Strong­bridge ob­tained an old and once cheap drug that had nabbed an FDA ap­proval for a rare dis­ease, and jacked a six-fig­ure price for pa­tients. And Mis­souri Sen­a­tor Claire Mc­Caskill says she wants to do some­thing to stop this — and pre­vent oth­ers from fol­low­ing what has be­come a well worn path.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER